title: Pioglitazone with imatinib in CML may reduce residual disease.
authors.forename: Vicki
authors.initials: V
authors.lastname: Brower
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage* / Q000009:adverse effects; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000473:pathology; D018365:Neoplasm, Residual; D000077205:Pioglitazone; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D045162:Thiazolidinediones; D000068877:Imatinib Mesylate; D000077205:Pioglitazone